Para preguntas en general por favor contacte a nuestro Servicio de Atención al Cliente:
Merck KGaA
Frankfurter Str. 250
64293 Darmstadt
Germany
Teléfono: +49 6151 72-0
Fax: +49 6151 72 2000
15 febrero 2012
cargando
Expression host strains for pETBlue™ and pTriEx™ vectors are lDE3 lysogens that also carry the compatible pLacI plasmid, encoding the lac repressor. The pLacI plasmid confers chloramphenicol resistance and provides enough lac repressor to inhibit transcription from the T7lac promoter in the absence of inducer. The NovaBlue host strain is recommended for initial cloning with pETBlue and pTriEx vectors due to its superior transformation efficiency and high yields of high-quality plasmid DNA.
Note that these strains are not recommended for use with pET, pACYCDuet™, pCDF, pRSF, pCOLADuet™ or pETcoco™ vectors.
.Origami B host strains carry the same trxB/gor mutations as the original Origami strains, except that they are derived from a lacZY mutant of BL21 to enable pecise control of expression levels by adjusting the concentration of IPTG. Thus the Origami B strains combine the desirable characteristics of BL21, Tuner™, and Origami hosts in one strain background. The trxB and gor mutations are selectable on kanamycin and tetracycline, respectively; therefore, these strains cannot be used with the plasmids carrying kanamycin or tetracycline resistance genes. These strains also include the lon and ompT deficiences of BL21, which increase protein stability.
DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG. Genotype: F– ompT hsdSB (rB– mB–) gal dcm lacY1 ahpC (DE3) gor522::Tn10 trxB pLacI (CamR, KanR, TetR)
Note that these strains are not recommended for use with pET, pACYCDuet™, pCDF, pRSF, pCOLADuet™ or pETcoco™ vectors.
.Origami B host strains carry the same trxB/gor mutations as the original Origami strains, except that they are derived from a lacZY mutant of BL21 to enable pecise control of expression levels by adjusting the concentration of IPTG. Thus the Origami B strains combine the desirable characteristics of BL21, Tuner™, and Origami hosts in one strain background. The trxB and gor mutations are selectable on kanamycin and tetracycline, respectively; therefore, these strains cannot be used with the plasmids carrying kanamycin or tetracycline resistance genes. These strains also include the lon and ompT deficiences of BL21, which increase protein stability.
DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG. Genotype: F– ompT hsdSB (rB– mB–) gal dcm lacY1 ahpC (DE3) gor522::Tn10 trxB pLacI (CamR, KanR, TetR)
| Productos relacionados | |
|---|---|
| 70629 | Origami™(DE3)pLacI Competent Cells |
| 70920 | Rosetta™(DE3)pLacI Competent Cells |
| 71056 | Rosetta-gami™(DE3)pLacI Competent Cells |
| 71060 | RosettaBlue™(DE3)pLacI Competent Cells |
| Productos relacionados para Origami™ B(DE3)pLacI Competent Cells | |
| 70629 | Origami™(DE3)pLacI Competent Cells |
| 70920 | Rosetta™(DE3)pLacI Competent Cells |
| 71056 | Rosetta-gami™(DE3)pLacI Competent Cells |
| 71060 | RosettaBlue™(DE3)pLacI Competent Cells |
| Información sobre producto | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Components |
|
||||||||||||||||||
| Guaranteed efficiency | Guaranteed efficiency: > 2 x 106 cfu/μg | ||||||||||||||||||
| Almacenar y enviar información | |||
|---|---|---|---|
| Categoría de alamacenamiento | ≤ -70°C | ||
| Ship |
Dry Ice Only
Multiple Toxicity Values, refer to MSDS |
||
| Licence Brookhaven | This product is covered under license from Brookhaven National Labs. Commercial entities need to obtain a research use license prior to purchase. Please contact your licensing department to confirm that your company already holds a research use license. | ||
